Advertisement

Topics

PRospective Multiple Myeloma Impact Study

2016-09-22 20:53:26 | BioPortfolio

Summary

This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in active Multiple Myeloma patients.

Description

This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in active MM patients.

Eligible patients will have their tumor sample analyzed for the prognostic MMprofiler SKY92, several cytogenetic markers, gene expression markers, and gene expression clusters.

A total of 250 patients will be enrolled from up to 7 US centers. Patients will be followed 5 years after diagnosis.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Conditions

Multiple Myeloma

Intervention

MMprofiler SKY92 gene signature

Status

Not yet recruiting

Source

SkylineDx

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-09-22T20:53:26-0400

Clinical Trials [1395 Associated Clinical Trials listed on BioPortfolio]

Follow-Up of Patients With Breast Cancer or Multiple Myeloma Previously Treated on a Gene Therapy Clinical Trial

RATIONALE: Studying the long-term effects of gene therapy in patients with breast cancer or multiple myeloma over time may help doctors plan better treatment and follow-up. PURPOSE: This ...

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

The purpose of this study is to see if the investigator can help the immune system to work against myeloma. Because cancer is produced by the patients own body, the immune system does not ...

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as...

MMRF Molecular Profiling Protocol

Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled ...

PubMed Articles [16427 Associated PubMed Articles listed on BioPortfolio]

Polycythaemia: an unusual presentation of multiple myeloma.

In contrast to anaemia, polycythaemia is a distinctly uncommon finding in patients with multiple myeloma. We describe the presence of otherwise unexplained polycythaemia in a 57-year-old Caucasian man...

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demo...

Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.

A platelet membrane-coated biomimetic nanocarrier, which can sequentially target bone microenvironment and myeloma cells to enhance the drug availability at the myeloma site and decrease the off-targe...

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Multiple myeloma cell growth relies on intrinsic aggressiveness, due to a high karyotypic instability, or on the support from bone marrow (BM) niche.We and other groups have provided evidences that No...

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with...

Medical and Biotech [MESH] Definitions

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

The ability of fungi to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutations.

The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation.

More From BioPortfolio on "PRospective Multiple Myeloma Impact Study"

Quick Search
Advertisement
 

Relevant Topics

Gene Expression
The process of gene expression is used by eukaryotes, prokaryotes, and viruses to generate the macromolecular machinery for life. Steps in the gene expression process may be modulated, including the transcription, RNA splicing, translation, and post-tran...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Searches Linking to this Trial